Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cell Therapy for Diabetic Critical Limb Ischemia
NCT02287974Phase 2Terminated
- Start
- Sep 2011
- Primary completion
- Jul 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous bone marrow-derived mononuclear cell, autologous CD133+ cells and autologous adipose-derived mesenchymal stromal cells in critical limb ischemia (CLI) and type 2 diabetes mellitus (T2DM) (4 arms). Primary endpoint: Serious Adverse Events at 6 months. Started Sep 2011; status: terminated.
02
Drugs
autologous bone marrow-derived mononuclear cellautologous CD133+ cellsautologous adipose-derived mesenchymal stromal cells
03
Conditions
critical limb ischemia (CLI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02287974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287974.